• 90% YoY core test volume growth, on track for >24,000 core tests and regional break-even
• Microbiome Explorer now 55% of total revenue
• Diagnostic testing advancement with innovator, early adopter, and early majority segments

Microba Life Sciences (ASX: MAP) has released its Q2 FY26 Investor Presentation and Webinar, highlighting key financial and business highlights. The company reported a 90% year-over-year increase in core test volumes, putting it on track to exceed 24,000 core tests and achieve regional break-even targets. Microbiome Explorer now accounts for 55% of total revenue, demonstrating the success of the company's core clinical testing offering. Microba is advancing its diagnostic testing strategy, progressing from the innovator phase into the early adopter and early majority segments across its key markets of Australia, the United Kingdom, the United States, and Europe. The company is leveraging AI-driven transformation to drive efficiency gains and improve customer experiences, with examples including a 71.4% rate of enquiries resolved by the AI agent and a 94.7% satisfaction score. New product feature releases, such as the Oral Species Biomarker, Pay on Invoice, and Sunday collection and simplified instructions, are further enhancing the Microbiome Explorer offering and driving customer adoption.

FY26 break-even milestones: Based on operating break-even at a regional level (forecasted to be achieved at test volumes of >24,000, split across Australia and the UK). Break-even figures are on a regional EBITDA basis only and exclude Corporate, Product Development Expenditure and Share Based Payments expense.

Microba is building the platform for personalised, microbiome-based healthcare. Key strategic objectives include achieving regional break-even in Australia and the United Kingdom, strong YoY core test growth in Australia and the UK, initial market penetration in the United States and Europe, and delivering transformative patient outcomes across core regions.